Hyperkalemia-related Heart Failure Therapy Discontinuation and the Association with Outcomes in Patients with Heart Failure
Preprint
Abstract
Background: Renin-angiotensin-aldosterone system (RAAS) inhibitors are essential treatments for heart failure (HF) patients, but their use is often limited by hyperkalemia. Objective: This study assesses the incidence of hyperkalemia in chronic HF patients on RAAS inhibitors, examines changes in therapy following hyperkalemia episodes, and evaluates the impact of RAAS inhibitor discontinuation or down-titration on patient outcomes. Methods: We conducted a population-based cohort study of patients hospitalized or visiting the emergency department in Alberta for chronic HF from April 2012 to March 2020, focusing on those with RAAS inhibitor-associated hyperkalemia. Episodes of hyperkalemia (K >5.0 mmol/L) were monitored, and patients were followed for 30 days to determine if their RAAS therapy was maintained, reduced, or discontinued. Results: Among 7527 HF patients, we identified 123,038 RAAS inhibitor treatment years, resulting in 17 hyperkalemia events per 100 treatment years. Hyperkalemia led to RAAS inhibitor discontinuation in 35.2% of cases, down-titration in 8.4%, and continuation in 56.4%. Discontinuation or down-titration was more common when serum potassium exceeded 6.0 mmol/L (49.4%) compared to lower levels. Over a median follow-up of 1.4 years, discontinuing or down-titrating RAAS inhibitors was associated with increased all-cause mortality (aHR 1.80), higher cardiovascular hospitalizations (aHR 1.09), and more frequent ED visits for HF (aHR 1.17) compared to continued therapy. Conclusions: Discontinuation or down-titration of RAAS inhibitors in HF patients is associated with higher mortality and cardiovascular events. Strategies to maintain RAAS therapy after hyperkalemia episodes may improve patient outcomes.Keywords
This publication has 41 references indexed in Scilit:
- Frequency and Clinical Impact of Hyperkalaemia Within a Large, Modern, Real-World Heart Failure PopulationESC Heart Failure, 2020
- Unravelling the Interplay Between Hyperkalaemia, Renin–Angiotensin–Aldosterone Inhibitor Use and Clinical Outcomes. Data from 9222 Chronic Heart Failure Patients of the ESC-HFA-EORP Heart Failure Long-Term RegistryEuropean Journal of Heart Failure, 2020
- Incidence, Predictors and Clinical Management of Hyperkalaemia in New Users of Mineralocorticoid Receptor AntagonistsEuropean Journal of Heart Failure, 2018
- Factors Associated with Underuse of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction: An Analysis of 11 215 Patients from the Swedish Heart Failure RegistryEuropean Journal of Heart Failure, 2018
- 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart FailureEuropean Journal of Heart Failure, 2016
- Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal FunctionJACC, 2013
- Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart FailureJACC, 2012
- Eplerenone Survival Benefits in Heart Failure Patients Post-Myocardial Infarction Are Independent From its Diuretic and Potassium-Sparing EffectsJACC, 2011
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialThe Lancet, 2003
- Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart FailureJAMA, 1995